Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes†

著录项

• 来源
  《European Journal of Heart Failure》 |2012年第9期|p.1056-1066|共11页
• 作者

  Mihai Gheorghiade1* Stephen J. Greene2 Gerasimos Filippatos3 Erland Erdmann4 Roberto Ferrari5 Phillip D. Levy6 Aldo Maggioni7 Christina Nowack8 Alexandre Mebazaa9 and on behalf of the COMPOSE Investigators and Coordinators;

  展开▼
• 作者单位

  1Centre for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, 645 North Michigan Ave., Suite 1006, Chicago, IL 60611, USA 2Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA 3Heart Failure Unit, Department of Cardiology, Attikon University Hospital, Athens, Greece 4Herzzentrum der Universität zu Köln, Cologne, Germany 5Department of Cardiology and LTTA Centre, University Hospital of Ferrara and Salvatore Maugeri Foundation, IRCCS, Lumezzane, Italy 6Department of Emergency Medicine, Wayne State University School of Medicine, Detroit, MI, USA 7ANMCO Research Centre, Florence, Italy 8Global Clinical Development, Bayer Pharma AG, Wuppertal, Germany 9AP-HP, Department of Anaesthesiology and Critical Care Medicine, Hôpit;

  展开▼
• 收录信息
• 原文格式 PDF
• 正文语种 eng
• 中图分类
• 关键词